Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

TTR (Transthyretin) Stabilizers Are Associated With Improved Survival in Patients With TTR Cardiac Amyloidosis.

Rosenblum H, Castano A, Alvarez J, Goldsmith J, Helmke S, Maurer MS.

Circ Heart Fail. 2018 Apr;11(4):e004769. doi: 10.1161/CIRCHEARTFAILURE.117.004769.

PMID:
29615436
2.

Genetic Infiltrative Cardiomyopathies.

Sweet ME, Mestroni L, Taylor MRG.

Heart Fail Clin. 2018 Apr;14(2):215-224. doi: 10.1016/j.hfc.2017.12.003. Review.

3.

Treatment With Tafamidis Slows Disease Progression in Early-Stage Transthyretin Cardiomyopathy.

Sultan MB, Gundapaneni B, Schumacher J, Schwartz JH.

Clin Med Insights Cardiol. 2017 Sep 18;11:1179546817730322. doi: 10.1177/1179546817730322. eCollection 2017.

4.

Assessing risk for Mendelian disorders in a Bronx population.

diSibio G, Upadhyay K, Meyer P, Oddoux C, Ostrer H.

Mol Genet Genomic Med. 2017 Jul 6;5(5):516-523. doi: 10.1002/mgg3.307. eCollection 2017 Sep.

5.

Pathogenic Mutations Induce Partial Structural Changes in the Native β-Sheet Structure of Transthyretin and Accelerate Aggregation.

Lim KH, Dasari AKR, Ma R, Hung I, Gan Z, Kelly JW, Fitzgerald MC.

Biochemistry. 2017 Sep 12;56(36):4808-4818. doi: 10.1021/acs.biochem.7b00658. Epub 2017 Aug 30.

6.

Semi-quantitative models for identifying potent and selective transthyretin amyloidogenesis inhibitors.

Connelly S, Mortenson DE, Choi S, Wilson IA, Powers ET, Kelly JW, Johnson SM.

Bioorg Med Chem Lett. 2017 Aug 1;27(15):3441-3449. doi: 10.1016/j.bmcl.2017.05.080. Epub 2017 May 26.

PMID:
28625364
7.

Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis.

Quarta CC, Gonzalez-Lopez E, Gilbertson JA, Botcher N, Rowczenio D, Petrie A, Rezk T, Youngstein T, Mahmood S, Sachchithanantham S, Lachmann HJ, Fontana M, Whelan CJ, Wechalekar AD, Hawkins PN, Gillmore JD.

Eur Heart J. 2017 Jun 21;38(24):1905-1908. doi: 10.1093/eurheartj/ehx047.

8.

Retinol binding protein 4 (RBP4) concentration identifies V122I transthyretin cardiac amyloidosis.

Arvanitis M, Simon S, Chan G, Fine D, Beardsley P, LaValley M, Jacobson D, Koch C, Berk JL, Connors LH, Ruberg FL.

Amyloid. 2017 Mar;24(sup1):120-121. doi: 10.1080/13506129.2017.1295371. No abstract available.

9.

Identification of Transthyretin Cardiac Amyloidosis Using Serum Retinol-Binding Protein 4 and a Clinical Prediction Model.

Arvanitis M, Koch CM, Chan GG, Torres-Arancivia C, LaValley MP, Jacobson DR, Berk JL, Connors LH, Ruberg FL.

JAMA Cardiol. 2017 Mar 1;2(3):305-313. doi: 10.1001/jamacardio.2016.5864.

11.

Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey).

Maurer MS, Hanna M, Grogan M, Dispenzieri A, Witteles R, Drachman B, Judge DP, Lenihan DJ, Gottlieb SS, Shah SJ, Steidley DE, Ventura H, Murali S, Silver MA, Jacoby D, Fedson S, Hummel SL, Kristen AV, Damy T, Planté-Bordeneuve V, Coelho T, Mundayat R, Suhr OB, Waddington Cruz M, Rapezzi C; THAOS Investigators.

J Am Coll Cardiol. 2016 Jul 12;68(2):161-72. doi: 10.1016/j.jacc.2016.03.596.

12.

Transthyretin Cardiac Amyloidosis in Black Americans.

Shah KB, Mankad AK, Castano A, Akinboboye OO, Duncan PB, Fergus IV, Maurer MS.

Circ Heart Fail. 2016 Jun;9(6):e002558. doi: 10.1161/CIRCHEARTFAILURE.115.002558. Review.

13.

Current and future treatment of amyloid diseases.

Ankarcrona M, Winblad B, Monteiro C, Fearns C, Powers ET, Johansson J, Westermark GT, Presto J, Ericzon BG, Kelly JW.

J Intern Med. 2016 Aug;280(2):177-202. doi: 10.1111/joim.12506. Epub 2016 May 10. Review.

14.

(11)C and (18)F Radiolabeling of Tetra- and Pentathiophenes as PET-Ligands for Amyloid Protein Aggregates.

Nordeman P, Johansson LB, Bäck M, Estrada S, Hall H, Sjölander D, Westermark GT, Westermark P, Nilsson L, Hammarström P, Nilsson KP, Antoni G.

ACS Med Chem Lett. 2016 Feb 18;7(4):368-73. doi: 10.1021/acsmedchemlett.5b00309. eCollection 2016 Apr 14.

15.

Autoimmune response to transthyretin in juvenile idiopathic arthritis.

Clement CC, Moncrieffe H, Lele A, Janow G, Becerra A, Bauli F, Saad FA, Perino G, Montagna C, Cobelli N, Hardin J, Stern LJ, Ilowite N, Porcelli SA, Santambrogio L.

JCI Insight. 2016 Feb;1(2). pii: e85633. Epub 2016 Feb 25.

16.

Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis.

Coelho T, Merlini G, Bulawa CE, Fleming JA, Judge DP, Kelly JW, Maurer MS, Planté-Bordeneuve V, Labaudinière R, Mundayat R, Riley S, Lombardo I, Huertas P.

Neurol Ther. 2016 Jun;5(1):1-25. doi: 10.1007/s40120-016-0040-x. Epub 2016 Feb 19. Review.

17.

Clinical, ECG and echocardiographic clues to the diagnosis of TTR-related cardiomyopathy.

Damy T, Maurer MS, Rapezzi C, Planté-Bordeneuve V, Karayal ON, Mundayat R, Suhr OB, Kristen AV.

Open Heart. 2016 Feb 8;3(1):e000289. doi: 10.1136/openhrt-2015-000289. eCollection 2016.

18.

Evolving landscape in the management of transthyretin amyloidosis.

Hawkins PN, Ando Y, Dispenzeri A, Gonzalez-Duarte A, Adams D, Suhr OB.

Ann Med. 2015;47(8):625-38. doi: 10.3109/07853890.2015.1068949. Epub 2015 Nov 27. Review.

19.

The Genetic Challenges and Opportunities in Advanced Heart Failure.

Hannah-Shmouni F, Seidelmann SB, Sirrs S, Mani A, Jacoby D.

Can J Cardiol. 2015 Nov;31(11):1338-50. doi: 10.1016/j.cjca.2015.07.735. Epub 2015 Aug 21. Review.

20.

Uncovering the Mechanism of Aggregation of Human Transthyretin.

Saelices L, Johnson LM, Liang WY, Sawaya MR, Cascio D, Ruchala P, Whitelegge J, Jiang L, Riek R, Eisenberg DS.

J Biol Chem. 2015 Nov 27;290(48):28932-43. doi: 10.1074/jbc.M115.659912. Epub 2015 Oct 12.

Supplemental Content

Support Center